Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sham Mailankody

Showing results (51-60 of 174) with videos related to

Pageof 18
Sort By:
Clinical Pharmacology and Therapeutics|September 26, 2023
CAR T-Cell Therapy for Multiple Myeloma: A Clinical Practice-Oriented ReviewNorah Layla Sadek, Bruno Almeida Costa, Karthik Nath, et al.
Leukemia|March 31, 2026
Pharmacokinetics of CAR T cells in multiple myeloma - the good, the bad, and the uglyMaximilian Merz, Eric Jurgens, David Fandrei, et al.
JAMA Network Open|February 24, 2021
Assessment of Outcomes Associated With the Use of Newly Approved Oncology Drugs in Medicare BeneficiariesAngela K Green, Michael Curry, Niti Trivedi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
Minimal residual disease: what are the minimum requirements?Mark Roschewski, Maryalice Stetler-Stevenson, Constance Yuan, et al.
Blood|February 8, 2012
Second malignancies after multiple myeloma: from 1960s to 2010sAnish Thomas, Sham Mailankody, Neha Korde, et al.
BMJ (Clinical Research Ed.)|March 9, 2018
Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational studyJeffrey Wagner, John Marquart, Julia Ruby, et al.
Leukemia & Lymphoma|October 21, 2010
Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myelomaSham Mailankody, Esther Mena, Constance M Yuan, et al.
Haematologica|December 5, 2014
Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trialsElisabet E Manasanch, Neha Korde, Sham Mailankody, et al.
JAMA Oncology|November 27, 2018
Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical TrialDickran Kazandjian, Neha Korde, Sham Mailankody, et al.
Leukemia & Lymphoma|November 7, 2017
CAR T cell therapy for multiple myeloma: where are we now and where are we headed?Arnab Ghosh, Sham Mailankody, Sergio A Giralt, et al.
Pageof 18

Showing results (51-60 of 174) with videos related to

Sort By:
Pageof 18
Clinical Pharmacology and Therapeutics|September 26, 2023
CAR T-Cell Therapy for Multiple Myeloma: A Clinical Practice-Oriented ReviewNorah Layla Sadek, Bruno Almeida Costa, Karthik Nath, et al.
Leukemia|March 31, 2026
Pharmacokinetics of CAR T cells in multiple myeloma - the good, the bad, and the uglyMaximilian Merz, Eric Jurgens, David Fandrei, et al.
JAMA Network Open|February 24, 2021
Assessment of Outcomes Associated With the Use of Newly Approved Oncology Drugs in Medicare BeneficiariesAngela K Green, Michael Curry, Niti Trivedi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
Minimal residual disease: what are the minimum requirements?Mark Roschewski, Maryalice Stetler-Stevenson, Constance Yuan, et al.
Blood|February 8, 2012
Second malignancies after multiple myeloma: from 1960s to 2010sAnish Thomas, Sham Mailankody, Neha Korde, et al.
BMJ (Clinical Research Ed.)|March 9, 2018
Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational studyJeffrey Wagner, John Marquart, Julia Ruby, et al.
Leukemia & Lymphoma|October 21, 2010
Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myelomaSham Mailankody, Esther Mena, Constance M Yuan, et al.
Haematologica|December 5, 2014
Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trialsElisabet E Manasanch, Neha Korde, Sham Mailankody, et al.
JAMA Oncology|November 27, 2018
Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical TrialDickran Kazandjian, Neha Korde, Sham Mailankody, et al.
Leukemia & Lymphoma|November 7, 2017
CAR T cell therapy for multiple myeloma: where are we now and where are we headed?Arnab Ghosh, Sham Mailankody, Sergio A Giralt, et al.
Pageof 18